Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/26/23 | EFFECT | Notice of Effectiveness |
|
1 | |
| 04/24/23 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 04/21/23 | ARS | Annual report to security holders |
|
156 | |
| 04/21/23 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 04/21/23 | DEF 14A | Definitive proxy statements |
|
67 | |
| 03/31/23 | 8-K | Current report filing |
|
   |
30 |
| 03/22/23 | UPLOAD | SEC-generated letter |
|
1 | |
| 03/16/23 | S-3 | Registration statement for specified transactions by certain issuers |
|
204 | |
| 03/16/23 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
7 | |
| 03/16/23 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
193 |
